Upcoming Discipline Hearings

Hearing Dates: February 8, 2023,

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Amro Noureldin, while engaged in the practice of pharmacy as a relief pharmacist and/or dispensing pharmacist at Shoppers Drug Mart Pharmacy […] in Kenora, Ontario (the “Pharmacy”), committed professional misconduct in that he stole, misappropriated, and/or took without authorization drugs from the Pharmacy, including but not limited to controlled drugs and substances.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Contravened a federal law with respect to the distribution, purchase, sale, or dispensing or prescribing of any drug or product, whose purpose is to protect or promote public health, and/or that is otherwise relevant to his suitability to practise, and in particular theft under $5,000, contrary to section 334(b) of the Criminal Code, as amended;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional;
• Engaged in conduct that is unbecoming of a member.

Hearing Dates: February 13, 2023,

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Mary Azzer, while engaged in the practice of pharmacy as Designated Manager and/or dispensing pharmacist at Family Care Pharmacy in Iroquois Falls, Ontario (the “Pharmacy”), and/or as a shareholder and/or director of the corporation that operates the Pharmacy, committed professional misconduct in that:

• On or about June 12, 2019, she permitted, consented to or approved, expressly or impliedly, the Pharmacy operating without a pharmacist being physically present;
• On or about June 12, 2019, she permitted, consented to or approved, expressly or impliedly, the sale and/or dispensing of drugs at the Pharmacy while no pharmacist was physically present, with respect to certain identified prescriptions;
• On or about June 12, 2019, she permitted, consented to or approved, expressly or impliedly, the dispensing of new prescriptions to patients without the patients being offered counselling by a pharmacist, with respect to certain identified prescriptions;
• On or about June 12, 2019, she permitted, consented to or approved, expressly or impliedly, the dispensing of prescriptions to patients without the prescriptions having been checked appropriately by a pharmacist, with respect to certain identified prescriptions;
• On or about June 12, 2019, she signed prescription hardcopies as dispensing pharmacist without having appropriately checked the prescriptions before they were dispensed to patients, with respect to certain identified prescriptions;
• On or about June 12, 2019, she delayed the dispensing of a methadone prescription to a patient experiencing acute opioid withdrawal, rather than directing the person presenting the prescription to a nearby pharmacy that could fill it promptly.

In particular, it is alleged that she:

• Failed to maintain a standard of practice of the profession;
• Falsified a record relating to her practice or a person’s health record;
• Contravened the Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those Acts, and in particular s. 146 and s. 149 of the Drug and Pharmacies Regulation Act;
• Contravened a federal, provincial or territorial law or municipal by-law with respect to the distribution, purchase, sale, or dispensing or prescribing of any drug or product, the administering of any substance, or the piercing of the dermis, and in particular s. C.01.041 of the Food and Drug Regulations, CRC, c 870, made under the Food and Drugs Act;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: February 27, 2023, February 28, 2023,

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Hansel Bulaclac, during the period March 2021 – December 31, 2021, as Designated Manager, director, and majority shareholder of the corporation that owned and operated Pharmasave Cadence Pharmacy in Toronto (“Pharmacy”), committed professional misconduct in that:

• In April 2021, he failed to submit a Notice of Intent to the Ontario College of Pharmacists (“College”) regarding the closing of the Pharmacy; and/or
• On or about April 29, 2021, he failed to remove all signs and symbols relating to the practice of pharmacy within or outside the Pharmacy; and/or
• On or before May 29, 2021, he failed to provide the College with a completed Pharmacy Closing Statement; and/or
• During the period April 29, 2021 to December 9, 2021, he:
  • Failed to remove all drugs and/or dispose of all drugs in the Pharmacy in an environmentally safe manner from the Pharmacy and as required by law; and/or
  • Failed to make reasonable efforts to give notice to Pharmacy patients about the closure of the Pharmacy, the location of their records, and the manner in which their records could be accessed; and/or
  • Failed to maintain all records and documents relating to the care of Pharmacy patients, including the original prescriptions, for a period of at least 10 years from the last recorded professional pharmacy service provided to each patient.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Contravened the Drug and Pharmacies Regulation Act and specifically sections 141, 147 and/or 157;
• Contravened one or more of the following:
  • Drug and Pharmacies Regulation Act, ss. 141, 147, and/or 157;
  • Food and Drug Regulations C.01.043, G.03.012; Narcotic Control Regulations ss. 43 and 45;
  • Personal Health Information Protection Act, s. 13;
  • O. Reg 264/16, s. 21;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: March 1, 2023,

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Augustine Daniar, since May 2019, while engaged in the practice of pharmacy as director, shareholder, owner, Designated Manager, and/or dispensing pharmacist at White Cedar Pharmacy in Thunder Bay, Ontario, committed professional misconduct in that he:

• Failed to keep records as required relating to his patients and/or his practice with respect to the drug product Suboxone;
• Falsified a record relating to his patients and/or his practice with respect to the drug product Suboxone;
• Signed or issued, in his professional capacity, a document he knew and/or ought to have known contained a false and misleading statement with respect to the drug product Suboxone;
• Submitted or permitted, consented to or approved, expressly or by implication, the submissions of an account or charge for products that he knew and/or ought to have known was false or misleading with respect to the drug product Suboxone.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required respecting his patients and/or his practice;
• Falsified a record relating to his patients and/or his practice;
• Signed or issued, in his professional capacity, a document that he knew and/or ought to have known contained a false or misleading statement;
• Submitted or permitted, consented to or approved, expressly or by implication, the submissions of an account or charge for products that he knew and/or ought to have known was false or misleading;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: May 1, 2023, May 2, 2023, May 3, 2023, May 10, 2023, May 12, 2023,

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Amani Awad committed professional misconduct in that she:

• Attempted to bribe, interfere, obstruct, threaten, and/or tamper with one or more witnesses in a hearing before the Discipline Committee of the Ontario College of Pharmacists regarding allegations of professional misconduct against her.

In particular, it is alleged that she:

• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and/or unprofessional;
• Engaged in conduct that is unbecoming a member.

This hearing commenced on July 4-8, 2022, and continued on November 7, 8, 9, 14, and 15, 2022.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Marilyn Adamo, while engaged in the practice of pharmacy as director, shareholder, owner, Designated Manager, and/or dispensing pharmacist at Lifestyle Pharmacy & Candy Bar I.D.A (the “Pharmacy”), committed professional misconduct with respect to the following:

• Failing to carry out or abide by an undertaking given to the College dated January 7, 2013 and/or breaching an Order of a panel of the Discipline Committee of the College dated June 2, 2015 and in particular, with respect to dispensing narcotics to a family member on or about November 27, 2020 and/or on or about January 5, 2021; and/or
• Providing pharmaceutical care to herself and/or one or more family members on one or more occasions from in or about February 2020 to in or about September 2020; and/or
• Adapting and/or renewing a drug, namely for some or all of certain identified drugs or products between January 2020 and June 2021, without doing the following, which she wase required to do:
  • Notifying the patient’s prescriber that she renewed/adapted the patient’s prescription, and/or recording in the patient’s record the date on which the patient’s prescriber was notified; and/or
  • Recording the information on the prescription and/or the patient record required by sections 37 and 38 of Ontario Regulation 202/94, made under the Pharmacy Act, 1991, S.O. c. 36; and/or
• Submitting (or permitting, consenting to or approving, expressly or impliedly, the submission of) an account or charge for medications using an intervention code that she knew or ought to have known was false or misleading on one or more occasions for Vyvanse dispensed to patient [Patient 1] from in or about January 2019 to in or about September 2020 and/or claims for medications dispensed to patient [Patient 2] from in or about November 2015 to in or about June 2021; and/or
• Billing (or permitting, consenting to or approving, expressly or impliedly, the billing) for dispensing fees at weekly intervals for compliance pack medications that were actually dispensed at bi-weekly or monthly intervals including dispensing fees charged for the medications dispensed to one or more of certain identified patients in or about March 2020, and/or certain identified patients from in or about April 2021 to in or about May 2021; and/or
• Creating (or permitting, consenting to or approving, expressly or impliedly, the creation of) false and/or misleading records indicating compliance pack medications were being dispensed at weekly intervals when the medications were actually being dispensed at bi-weekly or monthly intervals, including records for the medications dispensed to one or more of certain identified patients and/or other identified patients from in or about April 2021 to in or about May 2021; and/or
• Creating (or permitting, consenting to or approving, expressly or impliedly, the creation of) false and/or misleading records on one or more occasions by backdating claims and/or dispensing records to a date different than the date on which the records were created on one or more occasions, with respect to the medications that were dispensed to certain identified patients.

In particular, it is alleged that she:

• Contravened a term, condition or limitation imposed on her certificate of registration;
• Failed to maintain a standard of practice of the profession;
• Falsified a record relating to her practice or a person’s health record;
• Signed or issued, in her professional capacity, a document that she knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that she knew or ought to have known was false or misleading;
• Charged a fee or amount that was excessive in relation to the service or product provided;
• Contravened the Pharmacy Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those Acts, and in particular, sections 36, 37, and/or 38 of Ontario Regulation 202/94, as amended, made under the Pharmacy Act, 1991;
• Failed to comply with an Order of a panel of the Discipline Committee of the College;
• Failed to carry out or abide by an undertaking given to the College dated January 7, 2013;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and/or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Marilyn Adamo, while engaged in the practice of pharmacy as director, shareholder, owner, Designated Manager, and/or dispensing pharmacist at Lifestyle Pharmacy & Candy Bar I.D.A, committed professional misconduct with respect to the following:

• Failing (or permitting, consenting to or approving, expressly or impliedly, the failure) to keep records as required with respect to the one or more of certain identified drugs or products or services:
  • from in or about May 2020 to in or about October 2020; and/or
  • from in or about March 2018 to in or about April 2019; and/or
  • from in or about September 2018 to in or about December 2019; and/or
• Creating (or permitting, consenting to or approving, expressly or impliedly, the creation of) false and/or misleading records by using another registrant’s name and/or registration number as prescriber in the course of adapting and/or renewing prescriptions and/or completing related documentation for one or more of certain identified prescription numbers from in or about May 2020 to in or about October 2020; and/or
• Creating (or permitting, consenting to or approving, expressly or impliedly, the creation of) false and/or misleading records by backdating documentation on authorizing prescriptions and/or other related documentation with respect to one or more of certain identified prescription numbers from in or about September 2018 to in or about October 2020; and/or
• Submitting (or permitting, consenting to or approving, expressly or impliedly, the submission of) accounts or charges for services to the Ontario Drug Benefit Program that she knew or reasonably ought to have known were false or misleading for some or all of certain identified MedsCheck reviews and/or Pharmaceutical Opinion Program Claims that were non-compliant with the guidelines of the Ministry of Health and Long Term Care; and/or
• Submitting (or permitting, consenting to or approving, expressly or impliedly, the submission of) accounts or charges for services to the Ontario Drug Benefit Program that she knew or reasonably ought to have known were false or misleading by using another registrant’s name for some or all of certain identified MedsCheck review claims; and/or
• Submitting (or permitting, consenting to or approving, expressly or impliedly, the submission of) MedsCheck claims to the Ontario Drug Benefit Program by using a name other than her name, as set out in the College’s Register, namely “Marilyn Rau”, on one or more occasions, from in or about January 2019 to in or about January 2022; and/or
• Providing and/or billing (or providing and permitting, consenting to or approving, expressly or impliedly, the billing) for MedsChecks services specific to diabetes without having the required knowledge and/or training as required by the guidelines of the Ministry of Health and Long Term Care, on one or more occasions, from in or about April 2019 to December 2019.

In particular, it is alleged that she:

• Failed to maintain a standard of practice of the profession;
• Used a name other than her name, as set out in the register, in the course of providing services within the scope of practice of the profession;
• Failed to keep records as required respecting her patients or practice;
• Falsified a record relating to her practice or a person’s health record;
• Signed or issued, in her professional capacity, a document that she knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that she knew or ought to have known was false or misleading;
• Contravened the Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those Acts, and in particular:
  • sections 36, 37, and/or 38 of Ontario Regulation 202/94, as amended, made under the Pharmacy Act, 1991, S.O. 1991, c. 36; and/or
  • section 156 of the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H4;
  • section 20 and 21 of Ontario Regulation 264/16, as amended, made under the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H4;
  • Section 15(1) of the Ontario Drug Benefit Act, R.S.O. 1990, c. O.10, as amended; and/or
  • Sections 27 and/or 29 of Ontario Regulation 201/96, made under the Ontario Drug Benefit Act, R.S.O. 1990, c. O.10;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Riham Basyouny, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at Clairhurst Medical Pharmacy and/or Charles Pharmacy, both in Toronto, Ontario, from about January 1, 2021 to August 1, 2021, committed professional misconduct in that she:

• Processed prescriptions from Clairhurst Pharmacy at Charles Pharmacy for billing purposes, in relation to certain identified prescriptions;
• Failed to maintain accurate records, in relation to certain identified prescriptions;
• Failed to ensure that containers in which prescription drugs are dispensed are labelled in accordance with s. 156(3) of the Drug and Pharmacies Regulation Act, with respect to certain identified prescriptions.

In particular, it is alleged that she:

• Failed to maintain the standards of practice of the profession;
• Falsified records relating to her practice;
• Signed or issued, in her professional capacity, a document that she knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that she knew or ought to have known was false or misleading;
• Contravened the Pharmacy Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, or the regulations under those Acts, and in particular, section 156(3) of the Drug and Pharmacies Regulation Act;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Dumfour David Berko, while engaged in the practice of pharmacy as Designated Manager and/or dispensing pharmacist at the […] Pharmacy in […], Ontario, in the period from about [Identified Date A] to [Identified Date B], committed professional misconduct in that he:

• Sexually abused a patient, […]
• Failed to maintain appropriate professional boundaries with a patient, […]
• Provided a scheduled drug (Tylenol #3) to a patient, […], without a validly authorized prescription.

In particular, it is alleged that he:

• Sexually abused a patient;
• Failed to maintain a standard of practice of the profession;
• Contravened s. 155 of the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H.4;
• Contravened a federal or provincial law with respect to the distribution, purchase, sale, or dispensing or prescribing of any drug or product, specifically s. 155 of the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H.4, and s. 31(1) of the Narcotic Control Regulations, C.R.C., c. 1041;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

A motion in this matter was heard on April 27, 2021.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Hansel Bulaclac, during the period December 2021 – June 23, 2022 while a member of the Ontario College of Pharmacists (“College”), committed professional misconduct by:

• Sending emails and/or posting on social media, including on Facebook and LinkedIn, in which he alleged the College and/or its staff/and or its directors and/or its committee members were acting incompetently and/or unethically and/or fraudulently and/or were corrupt or variations of these allegations; and/or
• Sending the emails referred to, above, to recipients who were not employees of the College involved in the investigation of his practice or committee members who were responsible for the disposition of the investigation; and/or
• Using the College’s logo, names and graphics without consent in his social media posts including on Facebook and LinkedIn; and/or
• Posting personal information regarding [Name] on social media without her consent; and/or
• Posting unauthorized content on the [Pharmacy Name] Facebook pages without its consent.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances would reasonably be regarded by members as disgraceful, dishonourable or unprofessional;
• Engaged in conduct that is unbecoming a member.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Amin Dharamsi, while engaged in the practice of pharmacy as a Designated Manager and/or dispensing pharmacist at [the Pharmacy], and/or as a director and/or shareholder of the corporation that owned and/or operated the Pharmacy, committed professional misconduct with respect to the following incidents:

• Between about October 2, 2018 and January 23, 2019, he failed to take appropriate steps to ensure the destruction of narcotics, controlled drugs, and/or targeted substances;
• On at least one occasion between about October 2, 2018 and January 23, 2019, he asked staff member [Person A] to destroy narcotics, controlled drugs, and/or targeted substances in his absence and/or in a manner contrary to Health Canada’s guidelines for the destruction of narcotics, controlled drugs, and/or targeted substances;
• On one occasion between about October 2, 2018 and January 23, 2019, he removed narcotics, controlled drugs, and/or targeted substances from the Pharmacy’s premises without appropriate documentation and/or justification;
• Between about October 2, 2018 and January 23, 2019, he provided routine pharmaceutical care and/or dispensed prescriptions to himself and to family members;
• On multiple occasions between about October 2, 2018 and January 23, 2019, he attempted to create false and/or misleading pharmacy records by attempting to imitate the signature of another pharmacist on dispensing records, and/or he asked members of the Pharmacy’s staff to assist him in doing so;
• On or about November 1, 2018, he attempted to create false and/or misleading pharmacy records showing the dispensing of medication to patient [Patient 1] at a greater frequency than was actually dispensed, and/or he asked members of the Pharmacy’s staff to assist him in doing so;
• On at least one occasion between about October 2, 2018 and January 23, 2019, he asked members of the Pharmacy’s staff to dispense, and/or to assist in the dispensing of, drugs without the markings on the container required by s. 156(3) of the Drug and Pharmacies Regulation Act, RSO 1990, c H.4;
• On at least two occasions between about October 2, 2018 and February 8, 2019, he gave previously-dispensed drugs and/or products to members of the Pharmacy’s staff and asked that they return the drugs and/or products to the Pharmacy’s inventory for resale;
• On at least one occasion between about October 2, 2018 and January 23, 2019, he asked members of the Pharmacy’s staff to falsify, and/or to assist him in falsifying, frequency of dispensing forms, and in particular with respect to falsifying the date on which the forms were sent to prescribers;
• On at least one occasion between about October 2, 2018 and January 23, 2019, he asked members of the Pharmacy’s staff to falsify, and/or to assist him in falsifying, the Pharmacy’s records relating to documenting the calibration of the Pharmacy’s scale and/or the temperature of the Pharmacy’s refrigerator;
• On multiple occasions between about [specified date A] and [specified date B], he behaved inappropriately toward and/or in the presence of members of the Pharmacy’s staff, including with respect to the following:
  1. he raised his voice, and/or threw objects, and/or shouted, at members of the Pharmacy’s staff;
  2. he hugged and/or kissed staff member [Person B];
  3. he asked staff member [Person B] inappropriately personal questions;
  4. he harassed staff members[ Person B] and [Person A] by persistently contacting them outside of their working hours at their personal contact numbers and/or email addresses;
• On at least one occasion between about October 2, 2018 and January 23, 2019, he practised the profession while his ability to do so was impaired or adversely affected by a substance, condition, dysfunction, disorder or circumstance, including but not limited to Nabilone and/or Suboxone;
• On multiple occasions between about October 2, 2018 and January 23, 2019, including on December 18, 2018, December 20, 2018, and/or January 4, 2019, he referred to himself by the title “Doctor” or an abbreviation thereof, and/or he represented himself as holding the educational degree of Doctor of Pharmacy by using the abbreviation “Pharm. D” after his name, without justification or authority;
• Between about October 2, 2018 and January 23, 2019, he dispensed (or permitted, consented to or approved, expressly or impliedly, the dispensing of) certain identified medication to patients in combinations of strengths that were inappropriate having regard to the patients’ prescribed doses and the available strengths of the medications, without an appropriate clinical, therapeutic, or other reasonable basis;
• Between about October 2, 2018 and January 23, 2019, he charged (or permitted, consented to or approved, expressly or impliedly, the charging of) amounts that were excessive in relation to the service or product provided, and in particular, he charged dispensing fees for dispensing certain identified medication to patients in combinations of strengths that were inappropriate having regard to the patients’ prescribed doses and the available strengths of the medications, without an appropriate clinical, therapeutic, or other basis.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Practised the profession while his ability to do so was impaired or adversely affected by any substance, condition, dysfunction, disorder or circumstance that he knew or ought to have known would impair or adversely affect his ability to practice;
• Inappropriately used a term, title or designation in respect of his practice;
• Charged a fee or amount that was excessive in relation to the service or product provided;
• Contravened the Pharmacy Act, 1991, the Drug and Pharmacies Regulation Act, the Regulated Health Professionals Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those acts, and in particular s. 33(1) of the Regulated Health Professions Act, 1991, SO 1991, c 18;
• Contravened a federal, provincial, or territorial law or municipal by-law with respect to the distribution, purchase, sale, or dispensing or prescribing of any drug or product, the administering of any substance, or the piercing of the dermis, and in particular s. 43 of the Narcotic Control Regulations, CRC, c 1041;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Raed Eid, while engaged in the practice of pharmacy as a pharmacist at [Pharmacy A] and/or [Pharmacy B] in [Location], Ontario and after the termination of his employment at the pharmacies, committed professional misconduct in that he:

• attended at [Pharmacy A] on two occasions and yelled at his former employer in public; and/or
• repeatedly called and/or texted his former employer; and/or
• attended at [Pharmacy B] on one or more occasions and video recorded and/or yelled at the owner and staff in the presence of patients; and/or
• sent emails to a number of persons in which he described his former employer and [Related Person] as being, among other things, disgusting and/or disrespectful and/or condescending and/or dishonest and/or racist, and/or incompetent, and/or falsely claimed that his former employer was going to stab him.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Raed Eid, during August 2021, while engaged in the practice of pharmacy as a pharmacist at [Pharmacy Name] in [Location], Ontario, committed professional misconduct in that he:

• Failed to provide a patient known as [Patient 1] with all of the Ramipril she was prescribed and/or verify dose and/or failed to provide [Patient 1] with medication for her daughter and/or was rude to [Patient 1];
• Failed to provide a patient known as [Patient 2] with her medication for depression and/or was rude to [Patient 2];
• Failed to provide a patient known as [Patient 3] with her medication, including but not limited to Elavil;
• Failed to provide patients known as [Patient 4] and [Patient 5] with their medications, including but not limited to [Patient 5]’s insulin;
• Failed to provide a patient known as [Patient 6] with his Keppra and/or provided the patient with the wrong quantity of Kadian;
• Failed to provide a patient known as [Patient 7] with her Cipralex and was rude to [Patient 7]; and/or
• Failed to maintain confidential patient information by questioning [Patient 8]’s mother in public about [Patient 8]’s medical conditions and other personal health information.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Raed Eid, while a member of the Ontario College of Pharmacists (“College”), committed professional misconduct in that he:

• Sent emails to and /or left voice mail messages for College staff in which he alleged that College staff members, including but not limited to one or more of [Person 1], [Person 2], [Person 3], [Person 4], [Person 5], [Person 6], [Person 7], and/or [Person 8] were incompetent and/or unethical and/or incapacitated and/or were acting illegally and/or were dishonest and/or racist and/or variations of these allegations, and/or he called them derogatory names and/or used profane language about them;
• Sent emails to and/or called and/or left voice mail messages for College staff members, including but not limited to one or more of [Person 1], [Person 2], [Person 4], [Person 7], and/or [Person 8], in which he threatened one or more of them;
• Sent emails to and/or called and/or left a voice mail message for [Person 1] after he had been cautioned by police on March 10, 2022 not to contact [Person 1];
• Sent emails and/or called and/or left voice mail messages for [Physician] and/or [Physician’s] staff that contained derogatory and/or threatening and/or profane language and/or sending emails containing derogatory, threatening and/or profane language about [Physician] and/or [Physician’s] staff to others; and/or
• Sent one or more of the emails referred to, above, to recipients who were not staff members of the College involved in the investigation of his conduct.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances would reasonably be regarded by members as disgraceful, dishonourable or unprofessional;
• Engaged in conduct that is unbecoming a member.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Shereen El-Azrak committed professional misconduct in that

• On September 25, 2018, in the Superior Court of Justice at Newmarket, she was found guilty of trafficking in fentanyl and possession of fentanyl for the purpose of trafficking, contrary to s. 5 of the Controlled Drugs and Substances Act, S.C. 1996, c. 19.

In particular, it is alleged that she

• Was found guilty of offences that are relevant to her suitability to practice.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Babatunde Fashina, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at Thistle Pharmacy in Brampton, Ontario, from about January 1, 2017 to December 31, 2020, committed professional misconduct in that he:

• Submitted false claims for one or more of certain identified drugs and other products that were not actually dispensed to patients; and
• Failed to keep records as required with respect to purchase invoices for certain identified drugs.

In particular, it is alleged that he:

• Failed to maintain the standards of practice of the profession;
• Failed to keep records as required respecting his patients or practice;
• Falsified records relating to his practice;
• Signed or issued, in his professional capacity, a document that he knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that he knew or ought to have known was false or misleading;
• Contravened the Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, or the regulations under those Acts, and in particular:
  • ss. 155 and 156 of the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H-4, as amended;
  • ss. 19(k) and 20(1), para. 4 of Ontario Regulation 264/16, made under the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H-4, as amended;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Maged Ghoubrial, from in or about February 2019 to in or about January 2021, while engaged in the practice of pharmacy as director, shareholder, owner, and/or pharmacist at St. Laurent IDA Pharmacy (the “Pharmacy”) in Gloucester, Ontario, committed professional misconduct in that he:

• Submitted (or permitted, consented to, or approved, expressly or by implication, the submission of) an account or charge for services or products that he knew and/or ought to have known was false or misleading with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims to the Ontario Drug Benefit Program;
• Falsified (or permitted, consented to or approved, expressly or by implication, the falsification of) a record regarding his patients and/or his practice with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims to the Ontario Drug Benefit Program;
• Signed or issued (or permitted, consented to, or approved, expressly or by implication, the signing or issuance of), in his professional capacity, a document he knew and/or ought to have known contained a false and/or misleading statement with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims to the Ontario Drug Benefit Program; and/or
• Failed to keep records as required regarding his patients and/or his practice with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims to the Ontario Drug Benefit Program.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required respecting his patients and/or practice;
• Falsified (or permitted, consented to or approved, expressly or by implication, the falsification of) a record relating to his practice and/or a person’s health record;
• Signed or issued (or permitted, consented to, or approved, expressly or by implication, the signing or issuance of), in his professional capacity a document that he knew or ought to have known contained a false or misleading statement;
• Submitted (or permitted, consented to, or approved, expressly or by implication, the submission of) an account or charge for services or products that he knew or ought to have known was false or misleading;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and/or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Maged Guerguis, while engaged in the practice of pharmacy as Designated Manager and/or dispensing pharmacist at […] in […] (the “Pharmacy”), committed professional misconduct in that:

• Between in or about [Date1] to in or about [Date 2], he failed to maintain the professional boundaries of the pharmacist-patient relationship when he developed and engaged in a non-professional, personal relationship with the patient, [Name 1];
• Between in or about [Date 1] to in or about [Date 2], he engaged in sexual abuse of the patient, [Name 1], on one or more occasions;
• Between in or about [Date 3] and [Date 4], he engaged in inappropriate conduct in relation to [Name 2], a pharmacy assistant employed at the Pharmacy, consisting of inappropriate comments, physical contact, unwelcome advances, and/or harassment;
• Between in or about October and November 2021, he engaged in inappropriate conduct towards Pharmacy staff, consisting of intimidating and/or aggressive comments and/or behaviour related to their conversations with College investigators who were investigating his conduct;
• Between in or about October and November 2021, he instructed, consented to, or approved (expressly or impliedly) the provision of false or misleading information to College investigators in the course of their investigation into his conduct; failed to cooperate with the investigation into his conduct; and/or obstructed or attempted to obstruct the investigation into his conduct, contrary to ss. 76(3) and/or 76(3.1) of the Health Professions Procedural Code, being Schedule 2 to the Regulated Health Professions Act, 1991;
• Between in or about January 2015 to in or about November 2021, he instructed and/or permitted staff to open the Pharmacy and/or to dispense medications to patients when a pharmacist was not physically present in the Pharmacy; and/or
• Between in or about January 2021 to in or about November 2021, he charged and/or submitted improper claims (or permitted, consented to, or approved, expressly or by implication, the charging and/or submission of improper claims) for one or more patients (including, but not limited to, certain identified patients) for dispensing fees for compliance packages at more frequent intervals than the compliance packages were being dispensed.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Abused a patient emotionally, verbally or physically;
• Failed to keep records as required respecting his patients or practice;
• Falsified a record relating to his practice and/or a person’s health record;
• Signed or issued, in his professional capacity, a document that he knew or ought to know contained a false or misleading statement;
• Submitted an account or charge for services and/or products that he knew or ought to know was false or misleading;
• Charged (or permitted, consented or approved, expressly or by implication, charges of) a fee and/or an amount that was excessive in relation to the service and/or product provided;
• Contravened the Pharmacy Act, 1991, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act, the Ontario Drug Benefit Act, or the regulations under those Acts, and particularly:
  • ss. 76(3) and/or 76(3.1) of the Health Professions Procedural Code, being Schedule 2 to the Regulated Health Professions Act, 1991, as amended;
  • ss.146 and/or 166 of the Drug and Pharmacies Regulation Act, as amended;
  • s. 15 of the Ontario Drug Benefit Act, as amended and/or ss. 18 and/or 27 of O. Reg. 201/96, as amended;
• Contravened a federal or provincial law or municipal by-law with respect to the distribution, purchase, sale, dispensing, or prescribing of any drug, drug product, mixture of drugs, the administering of any substance, or the piercing of the dermis; whose purpose is to protect or promote public health; and/or that is otherwise relevant to his suitability to practice, and particularly:
  • ss. 76(3) and/or 76(3.1) of the Health Professions Procedural Code, being Schedule 2 to the Regulated Health Professions Act, 1991, as amended;
  • ss.146 and/or 166 of the Drug and Pharmacies Regulation Act, as amended;
  • s. 15 of the Ontario Drug Benefit Act, as amended and/or ss. 18 and/or 27 of O. Reg. 201/96, as amended;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that John Kaldus, while practicing pharmacy as Designated Manager, director and shareholder, and/or dispensing pharmacist at Elliot Lake Health Centre Pharmachoice in Elliot Lake, Ontario and/or Robinson’s Pharmasave in Espanola, Ontario, in the period from about August 2014 to February 2018, committed professional misconduct in that he:

• Failed to keep records as required by the College’s Medication Procurement and Inventory Management Policy with respect to the inventory of narcotics and controlled drugs;
• Directed non-pharmacist employees to dispense methadone to patients;
• Misappropriated prescription drugs and/or controlled substances from the pharmacy, including:
  • Oxycocet;
  • Tylenol #3 and/or Ratio-Lenoltec #3;
  • Clonazepam; and/or
  • Tramadol.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required;
• Contravened s. 149(1) of the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H.4;
• Contravened a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, specifically
  • s. 4 of the Controlled Drugs and Substances Act;
  • s. 51(1) of the Benzodiazepines and Other Targeted Substances Regulations, SOR/2000-217;
  • s. 31(1) of the Narcotic Control Regulations, C.R.C., c. 1041
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that John Kaldus, while practicing pharmacy as Designated Manager, director and shareholder, and/or dispensing pharmacist at Elliot Lake Health Centre Pharmachoice in Elliot Lake, Ontario and/or Robinson’s Pharmasave in Espanola, Ontario, in the period from about December 2015 to April 2019, committed professional misconduct in that he:

• Failed to report to the Registrar that he had been charged criminally with offences under the Controlled Drugs and Substances Act on or about December 24, 2015;
• Unlawfully possessed the following controlled substances without a prescription when stopped by police in King Township, Ontario on December 24, 2015:
  • Oxycontin;
  • Oxycocet;
  • Oxycodone; and/or
  • Morphine.

In particular, it is alleged that he:

• Contravened a term, condition or limitation imposed on his certificate of registration;
• Failed to maintain a standard of practice of the profession;
• Contravened a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, specifically:
  • s. 4 of the Controlled Drugs and Substances Act, S.C. 1996, c. 19;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Jerome Kan, from in or about August 1, 2018 to in or about August 10, 2020, while engaged in the practice of pharmacy as director, shareholder, owner, Designated Manager, and/or dispensing pharmacist of Island Plaza Pharmacy, committed professional misconduct in that he:

• Submitted (or permitted, consented to or approved, expressly or by implication, the submission of) false, misleading, inaccurate, and/or unsubstantiated claims to the Ontario Drug Benefit Program (“ODBP”) for one or more of certain identified drugs and/or products; and/or
• • Failed to keep records as required with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims submitted to the Ontario Drug Benefit Program.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required respecting his patients or practice;
• Falsified records relating to his practice;
• Signed or issued, in his professional capacity, a document he knew or ought to have known contained a false or misleading statement;
• Submitted an account(s) or charge(s) for services that he knew and/or ought to have known was false or misleading;
• Contravened a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs and in particular: section 15 of the Ontario Drug Benefit Act, as amended;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Hany Komy, while engaged in the practice of pharmacy as […] at [the Pharmacy] in […], Ontario, committed professional misconduct in that he:

• Failed to maintain a professional boundary in respect of patient [Name], in the period from about [Specified Date 1] to [Specified date 2];
• Dispensed controlled-release oxycodone to patient [Name] on or about [Date A], [Date B], [Date C], and/or [Date D], instead of the short-acting oxycodone that had been prescribed.

In particular, it is alleged that he:

• Sexually abused a patient, [Name];
• Failed to maintain a standard of practice of the profession;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Hany Komy, while engaged in the practice of pharmacy as […] at the […] Pharmacy in […], Ontario, from about [Specified Date A] to [Specified Date B], committed professional misconduct in that he inappropriately touched a pharmacy employee, [Name].

In particular, it is alleged that he engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Hany Komy, […], committed professional misconduct in that he was found guilty of sexual assault contrary to section 271 of the Criminal Code of Canada and/or assault contrary to section 266 of the Criminal Code of Canada.

In particular, it is alleged that he:

• Was found guilty of an offence that is relevant to his suitability to practise;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Jaak Kubar, as dispensing pharmacist and/or Designated Manager of Burlington Drug Mart at 701 Guelph Line in Burlington, Ontario (the Pharmacy), and/or as a shareholder of the corporation that owned the Pharmacy, committed professional misconduct between approximately January 31, 2018 and July 31, 2020, in that he:

• Dispensed narcotic prescriptions to a single patient from two or more different prescribers without exercising appropriate professional diligence, communicating pertinent information to prescribers, and/or making adequate inquiries with the prescribers for one or more of certain identified drugs;
• Dispensed a monitored drug to one or more patient(s) without submitting the required information to the Narcotics Monitoring System as required by s. 8 of the Narcotics Safety and Awareness Act, 2010, S.O. 2010, c.22 and the Notice issued thereunder for one or more of certain identified transactions;
• Failed to adequately document the actions, if any, taken in response to, and/or the reasons for not taking any action in response to, one or more of certain identified Narcotics Monitoring System alerts; and/or
• Permitted and/or assisted a patient to conceal authorizations for Schedule I controlled substances from another prescriber, contrary to s. 4(2) of the Controlled Drugs and Substances Act.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required with respect to his patients or practice;
• Contravened the Pharmacy Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those Acts, and in particular: s. 8 of the Narcotics Safety and Awareness Act, 2010, S.O. 2010, c.22;
• Permitted, consented to, approved, counselled or assisted, whether expressly or by implication, the commission of an offence against any Act relating to the practice of pharmacy or the sale of drugs;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Accreditation Committee, it is alleged that Paul Lee, as Designated Manager of Specialty Rx (the “Pharmacy”), and as director Ottawa Pharmacy Group Inc. 4008255, c.o.b. as Specialty Rx and to whom the certificate of accreditation for the Pharmacy was issued, committed proprietary misconduct in that he:

• Failed to keep documents as required respecting patients, the operation of the Pharmacy and/or the practice of members practising in the Pharmacy;
• Returned to stock, resold, or re-dispensed a drug that was previously sold or dispensed; and/or
• Dispensed, sold or compounded a drug, or administered a substance, that was not of good quality and/or did not meet the standards required by law.

In particular, it is alleged that Paul Lee and Ottawa Pharmacy Group Inc. 4008255, as holder of the certificate of accreditation for Specialty Rx:

• Failed to maintain a standard of accreditation;
• Failed to keep documents as required respecting patients, the operation of the Pharmacy and/or the practice of members practising in the Pharmacy;
• Returned to stock, resold or re-dispensed a drug that was previously sold or dispensed;
• Dispensed, sold or compounded a drug, or administered a substance, that was not of good quality and/or did not meet the standards required by law;
• Engaged in conduct or performing an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Accreditation Committee, it is alleged that Michael Marini, the Designated Manager of Dover Apothecary in Port Dover, Ontario (the “Pharmacy”), and the Director of 740894 Ontario Inc., c.o.b. as Dover Apothecary and to which Certificate of Accreditation #30204 for the Pharmacy was issued, committed proprietary misconduct in that they:

• Failed to have available the references and resources for compounding that are required by members practising in the pharmacy to meet the standards of practice of the profession and to support the pharmacy services the members provide; and/or
• Failed to have the necessary systems to allow members of practicing in the Pharmacy to meet the standards of practice of the profession with respect to compounding;
• Failed to respond to the College’s request for an action plan in relation the Level III Assessment between on or about May 14, 2019 to on or about June 8, 2019; Level IV Assessment between on or about November 12, 2019 to on or about December 20, 2019; and/or Level V Assessment between on or about January 28, 2022 to on or about February 4, 2022; and/or
• Failed to respond to the College’s request for narcotic reconciliation records for the period of on or about February 24, 2021 to October 2021; and/or
• Failed to take all reasonable steps to correct some or all of the deficiencies identified in the Assessment Reports of June 20, 2018; October 23, 2018; May 6, 2019, and/or October 30, 2019 with respect to narcotics, controlled drugs and targeted substances reconciliation practices; compounding; and/or the patient consultation area, as identified; and/or
• Failed to conduct monthly narcotic reconciliations and/or submit them to the College’s Manager of Conduct Operations; and/or
• Failed to take steps to ensure that patient personal information is protected; and/or
• Failed to implement and follow policies and procedures to ensure all refrigerators that store medication are maintained at a temperature between 2 and 8 degrees Celsius.

In particular, it is alleged that Michael Marini, the Designated Manager of Dover Apothecary in Port Dover, Ontario (the “Pharmacy”), and the Director of 740894 Ontario Inc., c.o.b. as Dover Apothecary and to which Certificate of Accreditation #30204 for the Pharmacy was issued:

• Failed to maintain a standard of accreditation;
• Failed to reply within a reasonable time to a written or electronic inquiry or request from the College;
• Failed to carry out or abide by an undertaking given by the pharmacy to the College;
• Engaged in conduct or performing an act relevant to the operation of a pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Bichoy Maurice, as a shareholder and/or director at Olde Walkerville Pharmacy at 1701 Wyandotte Street East in Windsor, Ontario (the Pharmacy), committed professional misconduct with respect to the following:

• False or unsubstantiated claims submitted to the Ontario Drug Benefit Program (ODB) from the Pharmacy totaling approximately $720,053.73 between August 22, 2015 and August 22, 2017 for seven identified drugs, or any of them; and/or
• Improper claims for prescriptions and/or other products submitted to the ODB from the Pharmacy totaling approximately $23,894.70 in relation to one or more of certain identified claims.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Contravened, while engaged in the practice of pharmacy, a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular:
  • sections 5, 15, 17, 18 and/or 23 of the Ontario Drug Benefit Act; and/or
  • sections 18, 25 and/or 29(1) of Ontario Regulation 201/96; and/or
  • section 166 of the Drug and Pharmacies Regulation Act;
• Submitted an account or charge for services that he knew and/or ought to have known was false or misleading;
• Falsified a record relating to his practice;
• Signed or issued, in his professional capacity, a document he knew or ought to have known contained a false or misleading statement;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

A motion in this matter was heard on January 28, 2022.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Mina Michael, as a shareholder and/or director at Olde Walkerville Pharmacy at 1701 Wyandotte Street East in Windsor, Ontario (the Pharmacy), committed professional misconduct with respect to the following:

• False or unsubstantiated claims submitted to the Ontario Drug Benefit Program (ODB) from the Pharmacy totaling approximately $720,053.73 between August 22, 2015 and August 22, 2017 for seven identified drugs, or any of them; and/or
• Improper claims for prescriptions and/or other products submitted to the ODB from the Pharmacy totaling approximately $23,894.70 in relation to one or more of certain identified claims.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Contravened, while engaged in the practice of pharmacy, a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular:
  • sections 5, 15, 17, 18 and/or 23 of the Ontario Drug Benefit Act; and/or
  • sections 18, 25 and/or 29(1) of Ontario Regulation 201/96; and/or
  • section 166 of the Drug and Pharmacies Regulation Act;
• Submitted an account or charge for services that he knew and/or ought to have known was false or misleading;
• Falsified a record relating to his practice;
• Signed or issued, in his professional capacity, a document he knew or ought to have known contained a false or misleading statement;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

A motion in this matter was heard on January 28, 2022.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Rana Mimar, while engaged in the practice of pharmacy as Designated Manager, and/or dispensing pharmacist at Rexall Pharmacy at 260 St. Paul Avenue in Brantford, Ontario, committed professional misconduct in that she:

• Failed to keep records as required respecting her patients and/or practice with respect to Rx 5485771, Rx 5492592, COVaxON #DA-20488501, and/or COVaxON #DA-21049416 between in or about August 13, 2021 and in or about September 13, 2021;
• Falsified a record relating to her practice and/or a person’s health record with respect to Rx 5485771, Rx 5492592, COVaxON #DA-20488501, and/or COVaxON #DA-21049416 between in or about August 13, 2021 and in or about September 13, 2021;
• Signed or issued, in her professional capacity, a document that she knew or ought to have known contained a false or misleading statement with respect to Rx 5485771, Rx 5492592, COVaxON #DA-20488501, and/or COVaxON #DA-21049416 between in or about August 13, 2021 and in or about September 13, 2021; and/or
• Submitted (or permitted, consented to or approved, expressly or by implication, the submissions) charges for Rx 5485771 and/or Rx 5492592 that she knew or ought to have known were false and misleading between in or about August 13, 2021 and in or about September 4, 2021.

In particular, it is alleged that she:

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required respecting her patients and/or practice;
• Falsified a record relating to her practice and/or a person’s health record;
• Signed or issued, in her professional capacity, a document that she knew or ought to have known contained a false or misleading statement;
• Submitted (or permitted, consented to or approved, expressly or by implication, the submissions) charges that she knew or ought to have known were false and misleading;
• Contravened the Pharmacy Act, 1991, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those Acts in particular: Section 20(1) of Ontario Regulation 264/14;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Bishoy Nasralla, while employed as a staff pharmacist at Ziter Pharmachoice (the “Pharmacy”), and/or as a director and/or shareholder of the corporation that owned and operated the Pharmacy, committed professional misconduct from in or about March 1, 2018, to November 3, 2020, with respect to claims submitted with markups that were excessive and unreasonable, for some or all of certain identified drugs.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Charged (or permitted, consented to or approved, expressly or by implication, charges of) a fee or amount that was excessive in relation to the service or product provided;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Accreditation Committee, it is alleged that Noor Nooruzzaman, as Designated Manager of Noor Healthcare Pharmacy in Mississauga, Ontario (the “Pharmacy”), and as the Director of Nooruzzaman Inc., c.o.b. Noor Healthcare Pharmacy, and Nooruzzaman Inc., as the holder of Certificate of Accreditation #303588 for the Pharmacy, committed proprietary misconduct in that they:

1. Permitted, consented to or approved, either expressly or by implication, the operation of the Pharmacy without a pharmacist physically present on or about September 30, 2021; and/or
2. Failed to adequately maintain the pharmacy in a safe, clean, and/or orderly fashion with respect to:
   1. the inadequate storage of medication awaiting destruction and sharps containers in or about September 2021; and/or
   2. the inadequate monitoring/and or maintenance of fridge temperatures between in or about October 2019 and/or in or about September 2021; and/or
3. Failed to have adequate systems in place and/or adequate recordkeeping with respect to:
   1. Conducting and/or maintaining a record of, adequate inventory counts and/or reconciliations for narcotics, controlled drugs and/or targeted substances from in or about January 9, 2019 to in or about October 29, 2019; and/or in or about March, April, August and/or September 2021; and/or
   2. recording accurate information regarding prescriptions, specifically with respect to unsigned prescription hard copies on one or more occasions in and around April 2019, October 2019 and/or September 2021; and/or
   3. maintaining records in a manner that is auditable, traceable and/or allows for their easy retrieval with respect to Rx 053345 in and around October 2019 and Rxs N01391, N01430, and/or N01450 in and around September 2021

In particular, it is alleged that Noor Nooruzzaman, as Designated Manager of Noor Healthcare Pharmacy in Mississauga, Ontario (the “Pharmacy”), and as the Director of Nooruzzaman Inc., c.o.b. Noor Healthcare Pharmacy, and Nooruzzaman Inc., as the holder of Certificate of Accreditation #303588 for the Pharmacy:

• Failed to maintain any of the standards of accreditation;
• Failed to keep documents as required respecting patients, the operation of the pharmacy and/or the practice of members practicing in the pharmacy;
• Contravened the Drug and Pharmacies Regulation Act, the Pharmacy Act, 1991, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act, the Ontario Drug Benefits Act or the regulations under those Acts, in particular: section 146(1) of the Drug and Pharmacies Regulation Act, R.S.O. 1990, c. H.4;
• Contravened a federal, provincial or territorial law or any municipal bylaw with respect to the distribution, purchase, sale and/or dispensing of any drug product, where the purpose of the law or bylaw is to protect or promote public health or where the law or bylaw relates to the operation of the pharmacy or the provision of pharmacy services, in particular:
  • section 43 of the Narcotic Control Regulations, as amended; and/or
  • section G.03.012 under the Food and Drug Regulations, as amended; and/or
  • section 72 of the Benzodiazepines and Other Targeted Substances Regulations, as amended;
• Engaged in conduct or performed an act relevant to the operation of a pharmacy that, having regard to the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that John Palumbo, from in or about January 2019 to in or about November 2021, while engaged in the practice of pharmacy as director, shareholder, owner, Designated Manager, and/or dispensing pharmacist at Shoppers Drug Mart Pharmacy in Brampton, Ontario, committed professional misconduct in that he:

• Returned (or permitted, consented to, or approved, expressly or by implication, the returning of) drugs to stock without cancelling the prescription or refunding the claim;
• Dispensed (or permitted, consented to, or approved, expressly or by implication, the dispensing of) prescriptions without accurately recording the details of dispensing, including, but not limited to, the date of dispensing and the prescription number;
• Directed (or permitted, consented to, or approved, expressly or by implication) an unregulated staff member to perform some, or all, of the process of clinical/therapeutic verification of prescriptions; and/or
• Provided his login credentials to an unregulated staff member.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Failed to provide an appropriate level of supervision to a person he was professionally obligated to supervise;
• Failed to keep records as required respecting his patients and/or his practice;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and/or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Sina Salehi, committed professional misconduct with respect to the following incidents:

• While engaged in the practice of pharmacy as Designated Manager at Doctors Pharmacy in Scarborough, Ontario (“Doctors Scarborough”), and/or as a shareholder and/or director of the corporation that operated the pharmacy,

1. 1. between about January 1, 2019, and January 15, 2021, he diverted (or permitted, consented to, or approved, expressly or impliedly, the diversion of) prescription drugs to unauthorized recipients and/or sources, with respect to certain identified prescription drugs;
   2. between about January 1, 2019, and January 15, 2021, he submitted (or permitted, consented to, or approved, expressly or impliedly, the submission of) false or unsubstantiated claims for drugs and/or products that were not dispensed, with respect to certain identified drugs and/or products;
   3. between about January 1, 2019, and January 15, 2021, he dispensed (or permitted, consented to, or approved, expressly or impliedly, the dispensing of) prescription drugs without valid authorization, with respect to certain identified prescriptions;
   4. between about January 1, 2019, and January 15, 2021, he failed to ensure that inventory reconciliations of narcotics and controlled substances were performed at least once every six months, and/or he failed to ensure that records of such reconciliations were retained as required;
   5. between about January 1, 2019, and January 15, 2021, he failed to report the loss or theft of narcotics as required by s. 42 of the Narcotic Control Regulations made under the Controlled Drugs and Substances Act, and/or he failed to take all reasonable steps necessary to protect narcotics on his premises or under his control against loss or theft as required by s. 43 of the Narcotic Control Regulations made under the Controlled Drugs and Substances Act;

• While engaged in the practice of pharmacy as Designated Manager at Doctors Pharmacy in Thornhill, Ontario (“Doctors Thornhill”), and/or as a shareholder and/or director of the corporation that operated the pharmacy,

1. 1. between about April 1, 2019, and January 15, 2021, he diverted (or permitted, consented to, or approved, expressly or impliedly, the diversion of) prescription drugs to unauthorized recipients and/or sources, with respect to certain identified prescription drugs;
   2. between about April 1, 2019, and January 15, 2021, he submitted (or permitted, consented to, or approved, expressly or impliedly, the submission of) false or unsubstantiated claims for drugs and/or products that were not dispensed, with respect to certain identified drugs and/or products;
   3. between about April 1, 2019, and January 15, 2021, he dispensed (or permitted, consented to, or approved, expressly or impliedly, the dispensing of) prescription drugs without valid authorization, with respect to certain identified prescriptions;
   4. between about April 1, 2019, and January 15, 2021, he failed to ensure that inventory reconciliations of narcotics and controlled substances were performed at least once every six months, and/or he failed to ensure that records of such reconciliations were retained as required;
   5. between about April 1, 2019, and January 15, 2021, he failed to report the loss or theft of narcotics as required by s. 42 of the Narcotic Control Regulations made under the Controlled Drugs and Substances Act, and/or he failed to take all reasonable steps necessary to protect narcotics on his premises or under his control against loss or theft as required by s. 43 of the Narcotic Control Regulations made under the Controlled Drugs and Substances Act;

• While engaged in the practice of pharmacy at Neighbour’s Drug Mart in Thornhill, Ontario (“Neighbour’s Drug Mart”), and/or as a shareholder and/or director of the corporation that operated the pharmacy,

1. 1. between about August 4, 2020, and January 15, 2021, he diverted (or permitted, consented to, or approved, expressly or impliedly, the diversion of) prescription drugs to unauthorized recipients and/or sources, with respect to certain identified prescription drugs;
   2. between about August 4, 2020, and January 15, 2021, he submitted (or permitted, consented to, or approved, expressly or impliedly, the submission of) false or unsubstantiated claims for drugs and/or products that were not dispensed, with respect to certain identified drugs and/or products;
   3. between about August 4, 2020, and January 15, 2021, he failed to report the loss or theft of narcotics as required by s. 42 of the Narcotic Control Regulations made under the Controlled Drugs and Substances Act, and/or he failed to take all reasonable steps necessary to protect narcotics on his premises or under his control against loss or theft as required by s. 43 of the Narcotic Control Regulations made under the Controlled Drugs and Substances Act;

In particular, it is alleged that he

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required respecting his patients or practice;
• Falsified a record relating to his practice or a person’s health record;
• Submitted an account or charge for services or products that he knew or ought to have known contained a false or misleading statement;
• Contravened the Pharmacy Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991, the Narcotics Safety and Awareness Act, 2010, the Drug Interchangeability and Dispensing Fee Act or the Ontario Drug Benefit Act or the regulations under those Acts:
  • s. 155 of the Drug and Pharmacies Regulation Act
• Contravened a federal, provincial or territorial law or municipal by-law with respect to the distribution, purchase, sale, or dispensing or prescribing of any drug or product, the administering of any substance, or the piercing of the dermis:
  • s. C.01.041 of the Food and Drug Regulations, CRC, c 870, made under the Food and Drugs Act
  • s. 42 and/or s. 43 of the Narcotic Control Regulations made under the Controlled Drugs and Substances Act
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Amir Sedrak, from in or about February 2019 to in or about January 2021, while engaged in the practice of pharmacy as director, shareholder, owner, Designated Manager, and/or dispensing pharmacist at St. Laurent IDA Pharmacy (the “Pharmacy”) in Gloucester, Ontario, committed professional misconduct in that he:

• Submitted (or permitted, consented to, or approved, expressly or by implication, the submission of) an account or charge for services or products that he knew and/or ought to have known was false or misleading with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims to the Ontario Drug Benefit Program;
• Falsified (or permitted, consented to or approved, expressly or by implication, the falsification of) a record regarding his patients and/or his practice with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims to the Ontario Drug Benefit Program;
• Signed or issued (or permitted, consented to, or approved, expressly or by implication, the signing or issuance of), in his professional capacity, a document he knew and/or ought to have known contained a false and/or misleading statement with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims to the Ontario Drug Benefit Program; and/or
• Failed to keep records as required regarding his patients and/or his practice with respect to one or more of certain identified drugs and/or products and/or one or more of certain identified claims to the Ontario Drug Benefit Program.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Failed to keep records as required respecting his patients and/or practice;
• Falsified (or permitted, consented to or approved, expressly or by implication, the falsification of) a record relating to his practice and/or a person’s health record;
• Signed or issued (or permitted, consented to, or approved, expressly or by implication, the signing or issuance of), in his professional capacity, a document that he knew or ought to have known contained a false or misleading statement;
• Submitted (or permitted, consented to, or approved, expressly or by implication, the submission of) an account or charge for services or products that he knew or ought to have known was false or misleading;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable and/or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Mr. Shaheen while engaged in the practice of pharmacy as director, shareholder, Designated Manager and/or dispensing pharmacist in Ottawa, Ontario, committed professional misconduct in that he

• Engaged in the trafficking of controlled substance with respect to certain identified items
• Dispensed drugs and/or products for which prescriptions are legislatively required without an authorized prescriber’s authorization as set out for certain identified items
• In or about the period from January 2013 to March 2015, he failed to keep records as required by the Medication Procurement and Inventory Management Policy with respect to the inventory of narcotics and controlled drugs
• Submitted accounts or charges for services that he knew were false or misleading to the Ontario Drug Benefit program for one or more certain identified drugs and/or drug products
• Falsified pharmacy records relating to his practice in relation to claims made to the Ontario Drug Benefit program for one or more certain identified drugs and/or drug products
• From approximately January 2013 to March 2015, he used his position as pharmacist to traffic in narcotics, in particular fentanyl patches
• Procured an individual to carry out a simulated robbery of the IDA Rideau Pharmacy on October 26, 2014
• Made a report to the […] Police in respect of a robbery allegedly committed on October 26, 2014, knowing that the report was false

In particular, it is alleged that he

• Failed to maintain a standard of practice of the profession
• Failed to keep records as required respecting his patients
• Signed or issued, in his professional capacity, a document that he knew contained a false or misleading statement with respect to the certain identified forged prescriptions
• Submitted accounts or charges for services that he knew to be false or misleading
• Contravened the Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991 or the regulations under those Acts with respect to the following incidents:
  • Dispensing drugs and/or products in the absence of a prescription authorized by a prescriber in contravention of s. 40 of Ontario Regulation 58/11 under the Drug and Pharmacies Regulation Act and ss. 155 and 156
• Contravened, while engaged in the practice of pharmacy, a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular, and in particular, with respect to the following incidents:
  • Trafficking controlled substances in contravention of s. 5 of the Controlled Drugs and Substances Act
  • Dispensing drugs in the absence of a prescription authorized by a prescriber in contravention of s. 31 of the Narcotic Control Regulation
  • Selling drugs in the absence of a prescription authorized by a prescriber in contravention of C.01.041 of the Food and Drug Regulations
  • Selling drugs in the absence of a prescription authorized by a prescriber in contravention of G.03.002 of the Food and Drug Regulations
• Knowingly permitted the premises in which the pharmacy was located to be used for unlawful purposes
• Permitted, consented to or approved, either expressly or by implication, the commission of an offence against any Act relating to the practice of pharmacy or to the sale of drugs by a corporation of which he was a director
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Mr. Shaheen committed professional misconduct in that he

• Failed to comply with the decision of the Inquiries, Complaints and Reports Committee dated May 10, 2016, in that he failed to successfully complete the Professional Problem-Based Ethics workshop offered by the Center for Personalized Education for Physicians, at his own expense, within 12 months of the date of that decision, and provide proof thereof to the College.

In particular, it is alleged that he

• Failed to maintain a standard of practice of the profession
• Contravened the Act, the Drug and Pharmacies Regulation Act, the Regulated Health Professions Act, 1991 or the regulations under those Acts, namely: he contravened s. 26(3) of the Health Professions Procedural Code
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Mr. Shaheen, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at IDA Rideau Medical Pharmacy in Ottawa, Ontario, between May 2, 2011 and June 17, 2015, committed professional misconduct in that he

• Falsified pharmacy records relating to his practice in connection with claims made for certain identified drugs and/or other products and/or certain identified MedsCheck claims;
• Signed or issued, in his professional capacity, a document that he knew contained a false or misleading statement in connection with claims made for certain identified drugs and/or other products and/or certain identified MedsCheck claims;
• Submitted an account or charge for services that he knew was false or misleading in connection with claims made for certain identified drugs and/or other products and/or certain identified MedsCheck claims

In particular, it is alleged that he

• Failed to maintain a standard of practice of the profession
• Falsified pharmacy records relating to his practice
• Signed or issued, in his professional capacity, a document that he knew contained a false or misleading statement
• Submitted an account or charge for services that he knew was false or misleading
• Contravened a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular, sections 5, 6 and 15(1) of the Ontario Drug Benefit Act, R.S.O. 1990, c. O.10, as amended
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Michelle Shim, since in or around June 2017, while acting as Designated Manager, dispensing pharmacist and/or in any other capacity at Innomar Specialty Pharmacy in Barrie, Ontario, APlusPharma Ltd., Innomar Strategies Inc. and/or any other corporate entity affiliated with APlusPharma and/or Innomar Strategies, committed professional misconduct in that she:

• Practised the profession while in a conflict of interest as defined in Part II of Ontario Regulation 130/17 in relation to the drug product XYREM;
• Participated in an arrangement that constitutes a conflict of interest as defined in Part II of Ontario Regulation 130/17 with respect to the drug product XYREM;
• Entered into an agreement, in relation to the drug product XYREM, that restricted a person’s choice of a pharmacist without the consent of the person;
• Solicited and/or permitted the solicitation of patients to the Pharmacy in relation to the drug product XYREM; and/or,
• Participated in the transition to dispensing XYREM to the Pharmacy exclusively through the Pharmacy in a manner that contravened the principles of Beneficence, Respect for Persons/Justice and Accountability (Fidelity) in the Ontario College of Pharmacists Code of Ethics.

In particular, it is alleged that she:

• Failed to maintain a standard of practice of the profession;
• Practised the profession of pharmacy while in a conflict of interest and/or participated in an arrangement that constitutes a conflict of interest;
• Entered into an agreement that restricted one or more persons choice of a pharmacist without the consent of those person(s);
• Solicited and/or permitted the solicitation of one or more patients to the Pharmacy;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional;
• Engaged in conduct that is unbecoming a member.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Eddie Slama, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at Clairhurst Medical Pharmacy and/or CC Pharmacy, both in Toronto, Ontario, from about September 13, 2017 to May 23, 2019, committed professional misconduct in that he submitted false claims for one or more of certain identified drugs and other products when a different product was actually dispensed to patients.

In particular, it is alleged that he:

• Failed to maintain the standards of practice of the profession;
• Falsified records relating to his practice;
• Signed or issued, in his professional capacity, a document that he knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that he knew or ought to have known was false or misleading;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Eddie Slama, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at Clairhurst Medical Pharmacy and/or CC Pharmacy, both in Toronto, Ontario, from about January 1, 2016 to May 23, 2019, committed professional misconduct in that he submitted false claims for one or more of certain identified drugs and other products when a different product was actually dispensed to patients.

In particular, it is alleged that he:

• Failed to maintain the standards of practice of the profession;
• Falsified records relating to his practice;
• Signed or issued, in his professional capacity, a document that he knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that he knew or ought to have known was false or misleading;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Eddie Slama, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at Clairhurst Medical Pharmacy and/or CC Pharmacy, both in Toronto, Ontario, from about June 15, 2017 to August 29, 2019, committed professional misconduct in that he:

• Submitted false claims for one or more of certain identified drugs and other products when a different product was actually dispensed to patients;
• Dispensed free samples of prescription medication, namely compounded pain cream, without valid authorization.

In particular, it is alleged that he:

• Failed to maintain the standards of practice of the profession;
• Falsified records relating to his practice;
• Signed or issued, in his professional capacity, a document that he knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that he knew or ought to have known was false or misleading;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Eddie Slama, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at Clairhurst Medical Pharmacy and/or CC Pharmacy, both in Toronto, Ontario, from about January 1, 2016 to May 23, 2019, committed professional misconduct in that he submitted claims to [Claims Adjudicator] that included markups on drug products that were excessive and unreasonable.

In particular, it is alleged that he:

• Failed to maintain the standards of practice of the profession;
• Charged a fee that was excessive in relation to the service provided;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Eddie Slama, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at Clairhurst Medical Pharmacy and/or CC Pharmacy, both in Toronto, Ontario, from about January 9, 2018 to May 29, 2019, committed professional misconduct in that he dispensed and/or billed for certain identified prescription products in absence of a valid prescription.

In particular, it is alleged that he:

• Failed to maintain the standards of practice of the profession;
• Falsified records relating to his practice;
• Signed or issued, in his professional capacity, a document that he knew or ought to have known contained a false or misleading statement;
• Submitted an account or charge for services or products that he knew or ought to have known was false or misleading;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Eddie Slama, while engaged in the practice of pharmacy as dispensing pharmacist, Designated Manager, shareholder and/or director at Clairhurst Medical Pharmacy and/or CC Pharmacy, both in Toronto, Ontario, from about December 11, 2019 to about May 5, 2020, committed professional misconduct in that he caused prescriptions to be processed and billed through Main Drug Mart in Thornhill under the auspices of a central fill agreement.

In particular, it is alleged that he:

• Failed to maintain the standards of practice of the profession;
• Submitted an account or charge for services or products that he knew or ought to have known was false or misleading;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Renee St. Jean, since in or around March 2019, while acting as director, shareholder, owner, Designated Manager, dispensing pharmacist and/or in any other capacity at APlusPharma Ltd., Innomar Strategies Inc. and/or any other corporate entity affiliated with APlusPharma, Innomar Strategies, and/or Innomar Specialty Pharmacy in Barrie, Ontario, committed professional misconduct in that she:

• Practised the profession while in a conflict of interest as defined in Part II of Ontario Regulation 130/17 in relation to the drug product XYREM;
• Participated in an arrangement that constitutes a conflict of interest as defined in Part II of Ontario Regulation 130/17 with respect to the drug product XYREM;
• Entered into an agreement, in relation to the drug product XYREM, that restricted a person’s choice of a pharmacist without the consent of the person;
• Solicited and/or permitted the solicitation of patients to the Pharmacy in relation to the drug product XYREM; and/or,
• Participated in the transition to dispensing XYREM to the Pharmacy exclusively through the Pharmacy in a manner that contravened the principles of Beneficence, Respect for Persons/Justice and Accountability (Fidelity) in the Ontario College of Pharmacists Code of Ethics (the “Code of Ethics”).

In particular, it is alleged that she:

• Failed to maintain a standard of practice of the profession;
• Practised the profession of pharmacy while in a conflict of interest and/or participated in an arrangement that constitutes a conflict of interest;
• Entered into an agreement that restricted one or more persons choice of a pharmacist without the consent of those person(s);
• Solicited and/or permitted the solicitation of one or more patients to the Pharmacy;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional;
• Engaged in conduct that is unbecoming a member.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Shabuddin Syed committed professional misconduct in that he:

• Failed to successfully complete the ProBE Program on Ethics for Healthcare Professionals with an unconditional pass, at his expense, by the date required in an order of a panel of the Discipline Committee of the Ontario College of Pharmacists dated September 24, 2018 (the “Order”) and as extended by the Registrar of the Ontario College of Pharmacists, in accordance with the Order; and/or
• Failed to successfully complete, after successfully completing the ProBE Program, a course with Gail E. Siskind Consulting Services by the date required by the Order and as extended by the Registrar of the Ontario College of Pharmacists, in accordance with the Order.

In particular, it is alleged that he:

• Contravened a term, condition or limitation imposed on his certificate of registration;
• Failed to maintain a standard of practice of the profession;
• Failed to comply with an order of a panel of the Discipline Committee of the Ontario College of Pharmacists;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

Hearing Dates: TBA

Summary of Allegations

As a result of a referral by the Inquiries, Complaints and Reports Committee, it is alleged that Maged Tadros, as a director and/or shareholder of the corporation that owned and operated Ziter Pharmachoice, committed professional misconduct from in or about March 1, 2018, to November 3, 2020, with respect to claims submitted with markups that were excessive and unreasonable, for some or all of certain identified drugs.

In particular, it is alleged that he:

• Failed to maintain a standard of practice of the profession;
• Charged (or permitted, consented to or approved, expressly or by implication, charges of) a fee or amount that was excessive in relation to the service or product provided;
• Engaged in conduct or performed an act relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.